HMR59

Janssen buys up eye disorder gene therapy asset from Hemera Biosciences
Fierce Biotech
Wed, 12/2/20 - 10:45 am
Janssen
JNJ
Hemera Biosciences
gene therapy
HMR59
geographic atrophy